Ms Kimberley A Goldsmith BSc, MSc, MPH
Institute of Psychiatry
I trained as a basic scientist at McMaster University in Canada before obtaining a Master of Public Health in Biostatistics and Epidemiology at Oregon Health & Science University.
I have previous experience as a data manager and statistician in the areas of employment support for people with disabilities (in the United States), antimicrobial resistance, heart and lung diseases and clinical trials in mental health. I was a statistician in the Mental Health and Neurosciences CTU prior to commencing PhD studies.
activities and interests
My main research focus is mediation of the effects of psychotherapeutic treatments in clinical trials. This is part of a wider interest in studying causal inference. I am evaluating potential mediators in the PACE trial of treatments for chronic fatigue syndrome in collaboration with Trudie Chalder and the other PACE investigators. I am also using PACE, and possibly other trials of cognitive behavioural therapy, to study and develop methods such as instrumental variable estimation of mediated effects. Other interests include modelling longitudinal data and managing missing data in trials.
I am a demonstrator for the Introduction to Stata course and the Statistics course for Forensic MSc students.
McCrone P, Sharpe M, Chalder T, Knapp M, Johnson AL, Goldsmith KA, White PD. Adaptive pacing, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome: a cost-effectiveness analysis. PLoS One. 2012;7(8):e40808. Epub 2012 Aug 1.
White PD, Goldsmith KA, Johnson AJ, Potts L, Walwyn R, DeCesare JC, Baber HL, Burgess M, Clark LV, Cox DL, Bavinton J, Angus BJ, Murphy G, Murphy M, O’Dowd H, Wilks D, McCrone P, Chalder T, Sharpe M, on behalf of the PACE trial management group. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet, 2011; 377(9738):823-836.
Stoica S, Goldsmith K, Demiris N, Punjabi P, Berg G, Sharples L, Large S. Microsimulation and clinical outcomes analysis support a lower age threshold for use of biological valves. Heart, 2010; 96(21):1730-1736.
Goldsmith K, Dyer, M, Buxton, M, Sharples, L. Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease. Health and Quality of Life Outcomes, 2010; 8(1):54.
Dyer M, Goldsmith K, Sharples L, Buxton M. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health and Quality of Life Outcomes 2010; 8:13.
Goldsmith K, Dyer, M, Schofield, P, Buxton, M, Sharples, L. Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health and Quality of Life Outcomes, 2009; 7:96.
Goldsmith K, Demiris N, Gooi J, Sharples L, Dhital K, Jenkins D, Tsui S. Life-years gained by reducing donor heart ischaemic times. Transplantation 2009; 87(2):243-248.
Goldsmith K, Sharples LD, Sudarshan C, Parameshwar J, Tsui S, Wallwork J, Large S. Twenty-five years of heart transplantation at Papworth Hospital: Changes in factors influencing short- and long-term patient survival over time. Open Journal of Transplantation 2008; 2:13-20.
Dyer MT, Goldsmith K, Khan S, Sharples L, Freeman C, Hardy I, Buxton M, Schofield P. Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial. Trials 2008; 9:40.
Sharples L, Hughes V, Crean A, Dyer M, Buxton M, Goldsmith K, Stone D. Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial. The CECaT trial. Health Technology Assessment 2007; 11(49):iii-iv, ix-115.
last updated: Thursday, November 08, 2012